Literature DB >> 20487341

Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog.

Daisuke Izumi1, Masaomi Chinushi, Kenichi Iijima, Shizue Ahara, Satoru Komura, Hiroshi Furushima, Yukio Hosaka, Akiko Sanada, Nobue Yagihara, Yoshifusa Aizawa.   

Abstract

BACKGROUND: Bepridil (a multiple channel blocker) may markedly prolong the QT interval and induce polymorphic ventricular tachyarrhythmias (VTA). We compared the transmural ventricular repolarization characteristics and inducibility of polymorphic VTA after administration of bepridil versus the pure I(Kr) blocker, E-4031, each administered to five open-chest dogs.
METHODS: We used plunge needle electrode to record transmural left ventricular (LV) repolarization and activation-recovery interval (ARI) to estimate local repolarization. The correlation between paced cycle length and ARI was separately examined in the LV endocardium, mid-myocardium (Mid), and epicardium. Attempts to induce VTA were made during bradycardia and sympathetic stimulation.
RESULTS: Bepridil and E-4031 prolonged QT interval and ARI in all LV layers, though the magnitude of prolongation was greatest in Mid, increasing the transmural ARI dispersion, particularly during bradycardia. Compared with E-4031, bepridil caused mild, reverse use-dependent changes in ventricular repolarization, and less ARI dispersion than E-4031 during slow ventricular pacing. Both drugs increased ARI(max) and cycle length at 50% of ARI(max), though the changes were smaller after bepridil than after E-4031 administration. Bradycardia after the administration of each drug induced no VTA; however, sympathetic stimulation induced sustained polymorphic VTA in two of five dogs treated with E-4031 versus no dog treated with bepridil.
CONCLUSIONS: Unlike the pure I(kr) blocker, E-4031, bepridil exhibited weak properties of reverse use-dependency and protected against sympathetic stimulation-induced VTA. It may be an effective supplemental treatment for recipients of implantable cardioverter defibrillator.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20487341     DOI: 10.1111/j.1540-8159.2010.02768.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

1.  In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.

Authors:  Cunjin Luo; Kuanquan Wang; Henggui Zhang
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

2.  Bepridil, a class IV antiarrhythmic agent, can block the TREK-1 potassium channel.

Authors:  Ying Wang; Zhijie Fu; Zhiyong Ma; Na Li; Hong Shang
Journal:  Ann Transl Med       Date:  2021-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.